Get the Stockscreener App
760.27
0.36%
-2.77
Pre-market:
770.85
10.58
+1.39%
Regeneron Pharmaceuticals Inc stock is traded at $760.27, with a volume of 619.88K.
It is down -0.36% in the last 24 hours and up +0.05% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$763.04
Open:
$758.4
24h Volume:
619.88K
Relative Volume:
0.84
Market Cap:
$80.38B
Revenue:
$14.34B
Net Income/Loss:
$4.50B
P/E Ratio:
18.29
EPS:
41.5626
Net Cash Flow:
$3.77B
1W Performance:
-1.60%
1M Performance:
+0.05%
6M Performance:
+30.35%
1Y Performance:
+32.73%
1-Day Range:
$747.76
$761.91
1-Week Range:
$745.00
$781.21
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (REGN) Movement - Stock Traders Daily
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker - Benzinga
Monoclonal Antibody Therapeutics (Mabs) Market (2026-2033) | - openPR.com
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals - simplywall.st
Surprises Report: What are the future prospects of Regeneron Pharmaceuticals IncWeekly Market Outlook & Smart Swing Trading Techniques - baoquankhu1.vn
Targets Report: Is Regeneron Pharmaceuticals Inc gaining market shareQuarterly Earnings Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval - finance.yahoo.com
FDA approves expanded EYLEA HD dosing intervals - Eyes On Eyecare
All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy - finance.yahoo.com
Regeneron And TriNetX Partner To Expand Global Genomic And EHR Linked Data Platform - BioPharma APAC
Tritonpoint Wealth LLC Sells 1,938 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC - MarketBeat
2,145 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Perpetual Ltd - MarketBeat
Regeneron’s EYLEA HD Label Update Shifts Retinal Care And Competition - simplywall.st
Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock - MSN
REGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Regeneron Pharmaceuticals Inc (REGN) SEC filings - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Allspring Global Investments Boosts Stake in Regeneron Pharmaceuticals - National Today
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Regeneron Eyes Longer EYLEA HD Dosing As Valuation Gap Persists - finance.yahoo.com
Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc - GuruFocus
Regeneron (REGN) director Ryan sells $77,727 in stock By Investing.com - Investing.com South Africa
Regeneron Pharmaceuticals Inc (RGO.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron (REGN) director Ryan sells $77,727 in stock - Investing.com
Small Rule 10b5-1 sale by Regeneron (REGN) director Arthur F. Ryan - Stock Titan
Best Pharmaceutical Stocks To Follow TodayApril 3rd - MarketBeat
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance Australia
Regeneron Secures Two FDA Approvals in One Day: Does the Math Support an Above $1,200 Target? - TIKR.com
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation - FinancialContent
The Bull Case For Regeneron (REGN) Could Change Following New Dupixent BP Approval In JapanLearn Why - simplywall.st
Aberdeen Group Boosts Regeneron Pharmaceuticals Holdings - National Today
Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD - VisionMonday.com
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - finance.yahoo.com
FDA approves extended dosing for Regeneron’s EYLEA HD treatment By Investing.com - Investing.com Australia
Regeneron partners with TriNetX for health data access - Investing.com
Regeneron Pharmaceuticals announced that, as part of their strategic partnership, the company will invest up to 200 million dollars in Trinetx. - Bitget
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN34.SA) company profile and facts - Yahoo Finance Singapore
Regeneron says it expects to avoid new US pharma tariffs - Reuters
FDA Expands Dosing Flexibility for Regeneron's EYLEA HD - GuruFocus
FDA approves extended dosing for Regeneron’s EYLEA HD treatment - Investing.com
FDA lets some EYLEA HD patients cut eye injections to 2 or 3 a year - stocktitan.net
Ophthalmology Drugs Market: Current Landscape and Future Outlook - Barchart
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $825 - Moomoo
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
2.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):